Neon Therapeutics Announces Closing of Initial Public Offering

June 29, 2018 at 4:15 PM EDT

CAMBRIDGE, Mass., June 29, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq:NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced the closing of its initial public offering of 6,250,000 shares of common stock at a public offering price of $16.00 per share. The gross proceeds from the offering were $100.0 million before deducting underwriting discounts and commissions and estimated offering expenses.  In addition, the underwriters have a 30-day option to purchase up to 937,500 additional shares of common stock at the initial public offering price less underwriting discounts and commissions. All of the shares in the offering were offered by Neon Therapeutics. The shares commenced trading on the Nasdaq Global Select Market on June 27, 2018 under the ticker symbol “NTGN.”

Morgan Stanley, BofA Merrill Lynch and Mizuho Securities acted as joint book-running managers for the offering. Oppenheimer & Co. acted as lead manager for the offering.

The offering is being made only by means of a prospectus. Copies of the final prospectus may be obtained, when available, from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@baml.com; or Mizuho Securities USA LLC, Attention: Equity Capital Markets, 320 Park Ave., New York, New York 10022, or by e-mail at US-ECM@us.mizuho-sc.com, or by telephone at (212) 205-7600.

A registration statement relating to the shares being sold in this offering was declared effective by the Securities and Exchange Commission on June 26, 2018. Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Neon Therapeutics

Neon Therapeutics is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens.

Media Contact:

Stephanie Simon, Ten Bridge Communications
stephanie@tenbridgecommunications.com
617-581-9333

Investor Contact:

Will O'Connor, Stern Investor Relations
will@sternir.com
212-362-1200

Primary Logo

Source: Neon Therapeutics, Inc.